Elicio Therapeutics, Inc.

ELTX Nasdaq SEC CIK 1601485
Follow Elicio Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$8M +20.9% vs same quarter last year
EPS, diluted −$0.30 +50% vs same quarter last year
Operating cash flow −$10.4M +6.5% vs same quarter last year
Operating income −$8.5M −5.1% vs same quarter last year
Net income by quarter
−$14M
−$11.2M
−$10.6M
−$10.1M
−$7.7M
−$11.8M
−$8.2M
−$8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$39.6M
FY24-−$51.9M
FY23-−$35.2M
FY22$2.3M−$28.2M
FY21$28.3M−$54.6M
FY20$2.9M−$80.1M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%1000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY22100%−1031.4%−1225.9%
FY2198.5%−138.8%−192.8%
FY2058.7%−1919.2%−2781.5%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$37M
FY24−$37.2M
FY23−$32.8M
FY22−$22.8M
FY21−$53M
FY20−$22.9M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Elicio Therapeutics
  • Healthcare median
−3000%−2000%−1000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearElicio TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22−1225.9%−80.4%
FY21−192.8%−71.8%
FY20−2781.5%−62.2%
FY19-−46.2%